SUBSCRIBE: Print / Digital / eNewsletter
"Through all this, I have never been more optimistic that together we will be stronger both in the urologic community and the medical community as a whole," writes Steven A. Kaplan, MD.
"Professionally, I am mentally and logistically preparing for a different medical environment when we all return from isolation. I doubt it will ever be business as usual again," writes Bradley A. Erickson, MD, MS.
"We take online training for simulation of chemical spill, radiation, and infection, but there is no manual to follow in this burgeoning COVID-19 crisis," writes Gopal H. Badlani, MD.
"During these times of uncertainty, panic, and social distancing associated with COVID-19, the American Board of Urology is sensitive to the additional stress this pandemic has placed on urology practices and urologists’ ability to meet their certificate requirements," writes J. Brantley Thrasher, MD.
"While I understand there may be some hesitancy from the AUA to issue plain text examples of what an elective case is given the lack of hard data to support their conclusions and that in so many situations the details of a case can vary so much patient to patient, in this less-official non-AUA-sanctioned setting, I thought a list of what seems elective and what is more urgent would be helpful," writes Henry Rosevear, MD.
"As clinicians for patients requiring cancer care, we need to ensure that we are optimizing all precautions for both the elderly and for those with potential immunosuppression," writes Neal D. Shore, MD.
“It hasn’t become the gold standard yet. There are still a lot of inter-reader reliability issues. The same MRI scans, read by different radiologists, may be read differently," says one urologist.
"Given that most urologic outpatient visits are non-urgent, almost all in-person visits should be eliminated out of appropriate concern for COVID-19," advise Drs. Gadzinski, Ellimoottil, Odisho, Watts, and Gore.
ImmunityBio announced that the FDA has granted Breakthrough Therapy designation for its interleukin-15 agonist complex, N-803, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-unresponsive nonmuscle-invasive bladder carcinoma in situ.
"We are using a 'cell phone' waiting room. When a patient arrives, they call our front desk. Then we text or call them when their exam room is ready," says one urologist.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
